Analysis of local and systemic immunological responses after intra- tracheal, intra-nasal and intra-muscular administration of microsphere co- encapsulated Yersinia pestis sub-unit vaccines

Vaccine

Volumn 16, Issue 20, 1998, Pages 2000-2009

  Eyles, Jim E ^a   Spiers, Ian D ^a   Williamson, E Diane ^b   Alpar, H Oya ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Biodegradable microparticles; Co microencapsulation; Protective sub units

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; MICROSPHERE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; YERSINIA PESTIS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; DRUG DELIVERY SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; LUNG LAVAGE; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; YERSINIA PESTIS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BRONCHOALVEOLAR LAVAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; INJECTIONS, INTRAMUSCULAR; MICE; MICROSPHERES; PLAGUE VACCINE; PRIMARY PREVENTION; TRACHEA; YERSINIA PESTIS;

EID: 0032374350     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00089-9     Document Type: Article

References (40)

1. 1 O'Hagan, D.T. and Illum, L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Sys. 1990, 7, 35-98.
2. 2 Lee, V.H.L. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Sys. 1988, 5, 69-97.
3. 3 Geurkink, N. Nasal anatomy, physiology and function. J. Allergy Clin. Immunol. 1983, 72, 123-128.
4. 4 Komada, F., Iwakawa, S., Yamamoto, N., Sakakibara, H. and Okumura, K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 1994, 83, 863-867.
5. 5 Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., Mintzes, J., Deaver, D., Lotan, N. and Langer, R. Large porous particles for pulmonary drug delivery. Science 1997, 276, 1868-1871.
6. 6 Patton, J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 1996, 19, 3-36.
7. 7 O'Hagan, D.T., Ott, G.S. and Van Nest, G. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today. 1997, 3, 69-75.
8. 8 Walker, R.I. New strategies for using mucosal vaccination to achieve more effective immunisation. Vaccine 1994, 12, 387-400.
9. 9 Bienstock, J. The lung as an immunologie organ. Ann. Rev. Med. 1984, 35, 49-62.
10. 10 Brandenberg, P. Immune functions of human nasal mucosa and tonsils in health. In: Immunology of the Lung and Upper Respiratory Tract (Ed. Bienstock, J.). McGraw-Hill, New York, 1984, pp. 28-95.
11. 11 Spit, B.J., Hendriksen, E.G.J., Bruijntjes, J.P. and Kuper, C.F. Nasal lymphoid tissue in the rat. Cell and Tissue Research 1989, 255, 193-198.
12. 12 Carr, R.M., Lolachi, C.M., Albaran, R.G., Ridley, D.M., Montgomery, P.C. and O'Sullivan, N.L. Nasal-associated lymphoid tissue as as inductive site for rat tear IgA antibody responses. Immunol. Invest. 1996, 25, 387-396.
13. 13 McGhee, J.R., Mestecky, J.M., Dertzbaugh, M.T., Eldridge, J.H., Hirasawa, M. and Kiyono, H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10, 75-88.
14. 14 van der Brugge-Gamelkoorn, G.J. and Sminia, T. T-cells and T-cells subsets in rat bronchus associated lymphoid tissue (BALT) in situ and in suspension. Adv. Exp. Med. Biol. 1985, 186, 323-329.
15. 15 Morris, W., Steinhoff, M.C. and Russell, P.K. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994, 12, 5-11.
16. 16 Tabata, Y. and Ikada, Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polym. Sci. 1990, 94, 107-141.
17. 17 Nakaoka, R., Tabata, Y. and Ikada, Y. Adjuvant effect of biodegradable poly(DL-lactic acid) granules capable for antigen release following intraperitoneal injection. Vaccine 1996, 14, 1671-1676.
18. 18 O'Hagan, D.T., Palin, K., Davis, S.S., Artursson, P. and Sjohölm, I. Microparticles as potentially orally active immunologocal adjuvants. Vaccine 1989, 7, 421-424.
19. 19 Jenkins, P.G., Coombes, A.G.A., Yeh, M.K., Thomas, N.W. and Davis, S. Aspects of the design and delivery of microparticles for vaccine applications. J. Drug Targetting 1995, 3, 79-81.
20. 20 Illum, L., Farraj, N., Critchley, H. and Davis, S.S. Nasal administration of gentamicin using a novel microsphere delivery system. Int. J. Pharm. 1988, 46, 261-265.
21. 21 Alpar, H.O., Almedia, A.J. and Brown, M.R.W. Microspheres absorption by the nasal mucosa of the rat. J. Drug. Targetting 1994, 2, 147-149.
22. 22 Baker, E.E., Sommer, H., Foster, L.E., Meyer, E. and Meyer, K.F. Studies on immunisation against plague. J. Immun. 1952, 68, 131-145.
23. 23 Nakajima, R. and Brubaker, R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumour necrosis factor alpha. Infect. Immun. 1993, 61, 23-31.
24. 24 Nakajima, R., Motin, V.L. and Brubaker, R.R. Suppression of cytokines in mice by protein A-V fusion peptide and restoration of synthesis by active immunisation. Infect. Immun. 1995, 63, 3021-3029.
25. 25 Williamson, E.D., Eley, S.M., Griffin, K.F., Green, M., Russell, P., Leary, S.E.C., Oyston, P.C.F., Easterbrook, T., Reddin, K.M., Robinson, A. and Titball, R.W. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immun. Med. Microbiol. 1995, 12, 223-230.
26. 26 Williamson, E.D., Sharp, G.J.E., Eley, S.M., Vesey, P.M., Pepper, T.C., Titball, R.W. and Alpar, H.O. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 1996, 14, 1613-1619.
27. 27 Perry, R.D. and Fetherston, J.D. Yersinia pestis - etiologic agent of plague. Clin. Microbiol. Rev. 1997, 10, 35-66.
28. 28 Williamson, E.D., Eley, S.M., Stagg, A.J., Green, M.G., Russell, P. and Titball, R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine 1997, 15, 1079-1084.
29. 29 Eyles, J.E., Sharp, G.J.E., Williamson, E.D., Spiers, I.D. and Alpar, H.O. Intra nasal administration of poly lactic acid microsphere co-encapsulated Yersinia pestis sub-units confers protection from pneumonic plague in the mouse. Vaccine 1998, 16, 698-707.
30. 30 Leary, S.E.C., Williamson, E.D., Griffin, K.F., Russell, P., Eley, S.M. and Titball, R.W. Active immunisation with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 1995, 63, 2854-2858.
31. 31 Titball, R.W., Howells, A.M., Oyston, P.C.F. and Williamson, E.D. Expression of the Yersinia pestis capsular antigen F1 antigen) on the surface of an aroA mutant of salmonella typhimurium induces high levels of protection against plague. Infect. Immun. 1997, 65, 1926-1930.
32. 32 Beck, L.R., Cowsar, D.H., Lewis, D.H., Cosgrove, U.R., Lowry, S.L. and Epperly, T.A. A new long-acting microcapsule system for administration of progesterone. Fertility Sterility 1979, 31, 545-551.
33. 33 Harmsen, A.G., Muggenberg, B.A. and Bice, D.E. The role of macrophages in particle translocation from lungs to lymph nodes. Science 1985, 230, 1277-1280.
34. 34 Eldridge, J.H., Staas, J.K., Chen, D., Marx, P.A., Tice, T.R. and Gilley, M. New advances in vaccine delivery systems. Seminars in Hematology 1993, 30, 16-25.
35. 35 Jakab, G.J. and Green, G.M. The effect of Sendai virus infection on bactericidal and transport mechanisms of the murine lung. J. Clin. Invest. 1971, 51, 1989-1998.
36. 36 Zee, Y.C., Osebold, J.W. and Dotson, W.M. Antibody responses and Interferon titres in the respiratory tracts of mice after aerosolized exposure to influenza virus. Infect. Immun. 1979, 25, 202-207.
37. 37 Andrews, G.P., Heath, D.G., Andersen, G.W., Welkos, S.L. and Friedlander, A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect. Immun. 1996, 64, 2180-2187.
38. 38 Vorontsov, E.D., Dubichev, A.G., Serdobinstev, L.N. and Naumov, A.V. Association-dissociation processes and super-molecular organisation of the capsule antigen protein (F1) of Yersinia pestis. Biomed. Sci. 1990, 1, 391-396.
39. 39 Li, V.H.K., Robinson, J.R. and Lee, V.H.L Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems. In: Controlled Drug Delivery: Fundamental and Applications (Eds Robinson, J.R. and Lee, V.H.L.). Marcel Dekker, New York, 1987, pp. 3-94.
40. 40 Anderson, G.W., Leary, S.E.C., Williamson, E.D., Titball, R.W., Welkos, S.L., Worsham, P.L. and Friedlander, A.M. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect. Immun. 1996, 64, 4580-4585.